Unlocking Value: 10 Discounted Stock Gems!

Value Radar: 10 Fresh Ideas + Full Valuation Deep-Dive on CVS Health (CVS)

Date: March 26, 2026 (United States)
Market anchor: The U.S. 10-year Treasury yield is at 4.35% today, up from 4.28% last week amid ongoing economic data and Fed signals.[1][2]


10 Fresh Value Candidates

Here are 10 new stocks trading at discounts to their fundamentals, with strong cash flows, dividends, or turnaround potential. These were selected from current screens for low forward price-to-earnings ratios (under 12x where possible), yields above 3%, and solid balance sheets—avoiding repeats from prior editions.

  • CVS Health (CVS): Healthcare giant with pharmacy, insurance, and clinics; 3.7% yield, ~10x forward earnings, record revenue.[3]
  • Ford (F): Auto leader pivoting to EVs and trucks; high yield ~5%, low 6x forward P/E, strong cash generation.
  • Boeing (BA): Aerospace recovery post-strikes; backlog supports growth, trades below book value.
  • Delta Air Lines (DAL): Airline with premium focus; record profits, 4% yield, low multiples amid travel boom.
  • Elevance Health (ELV): Health insurer (Anthem); undervalued at 12x earnings, robust margins.[4]
  • TotalEnergies (TTE): Energy major with dividends >5%, cheap on cash flow, transition to renewables.[4]
  • Arch Capital Group (ACGL): Insurer with low combined ratio; 13x P/E, growing book value.[4]
  • Synchrony Financial (SYF): Consumer finance; 5-7x earnings, high ROE.[5]
  • Sirius XM Holdings (SIRI): Audio streaming monopoly; 5%+ yield, cheap on subscribers.[6]
  • Lockheed Martin (LMT): Defense powerhouse; steady contracts, 2.5% yield, 16x earnings discount to growth.

CVS Health (CVS): The Deep Dive

CVS Health stands out as the top pick here—massive scale ($402B revenue in 2025), improving free cash flow (FCF), a 3.7% dividend yield, and trading at ~10x forward adjusted earnings despite headwinds like Medicare pressures. At $72/share and $92B market cap, it's undervalued versus peers and history.[7][8]

Business Overview

CVS operates three main segments:

  • Health Care Benefits (Aetna): 35% of revenue (~$143B in 2025), insures 27M+ members, earns via premiums minus claims.[9][10]
  • Health Services (CVS Caremark + Signify Health): 48% (~$193B), manages pharmacy benefits for employers/insurers and home health assessments.
  • Retail: 17% (~$68B), 9,000+ stores for drugs, front-store sales; shifting to health hubs.

2025 totals: $402B revenue (up 7.8%), but profits pressured by medical costs; adjusted operating income up 20.6% YoY.[11]

Roadmap and Growth Catalysts

  • Cost controls: $2B+ savings from efficiencies; Aetna margins to expand via better risk coding.[12]
  • Vertical integration: Leverage Aetna + Caremark + clinics (Oak Street Health, 300+ sites by 2026) for lower costs, higher retention. Oak Street pivot post-impairment now targets profitability.[13][14]
  • Guidance: 2026 revenue ≥$400B (flat but stable), adjusted EPS $7.00–$7.20 (double-digit growth), operating cash flow ≥$9B.[11][15] Dividend raised to $0.665/quarter ($2.66 annual).[16]

Current Landscape and Risks

Healthcare faces Medicare Advantage scrutiny (risk-adjusted payments down), competition from Amazon Pharmacy/Walgreens. CVS counters with scale (top PBM) and clinics. Balance sheet solid: $8B cash, but $60B debt (D/E 84%, manageable at 4.5x EBITDA). FCF up 23% to $7.8B in 2025.[17][18] Beta ~0.65 (defensive).[19]

Valuation: Ground-Up DCF and Comparables

Step 1: Key Assumptions (Cross-Referenced)

  • Revenue growth: 1% 2026 (guidance flat-ish amid costs), 4% 2027–2030 (Aetna/Signify ramp), 3% terminal (GDP+). Matches analyst EPS growth ~11% near-term.[11][20]
  • EBITDA margin: 3.9% 2025 (~$15.7B avg sources), to 4.2% 2026–2030 (op income guide $13.4B → adj ~$16B), 4.5% terminal. Historical avg 4%, peers 5–7%.[21][22]
  • Capex/Dep: 1% revenue (~$4B steady, historical).[18]
  • Tax: 21%. WC change: 0%.
  • FCF 2026 base: $9.5B (mid OCF guide $9B+ after capex; 2025 $7.8B up 23%).[15]
  • WACC: 7.0% (rf 4.35%, beta 0.7 avg [web:110], ERP 5.5% → CoE 8.2%; CoD 5.5% after-tax 4.3%; 65% equity/35% debt weights). Matches sources 5.5–9% avg.[23][24]
  • Terminal growth: 3% (conservative vs. 4% peers).
  • Net debt: $52B ($60B debt - $8B cash).[17]
  • Shares: 1.27B (buybacks $8.5B done).[25]

Step 2: FCFF Projections ($B)

Year Revenue EBITDA FCFF (EBIT(1-t)+D&A-Capex) PV @7%
2026 406 17.0 9.5 8.9
2027 422 18.0 10.1 8.8
2028 439 19.0 10.7 8.8
2029 457 20.1 11.4 8.8
2030 475 21.3 12.1 8.8
Terminal Value (2030) - - 202.5 (12.1* (1+3%)/(7%-3%)) 147.0
Total EV $190B

Equity value: $190B EV - $52B net debt = $138B → $109/share (base). Sensitivity: WACC 7.5%/$105; 6.5%/$114; growth +/-1% swings $95–$125.[26]

Step 3: Comparables Check

  • Peers (UNH, HUM, CI): Avg EV/EBITDA 12x (CVS 9.8x), fwd P/E 14x (CVS ~10x).[27][28]
  • Apply 11x EV/EBITDA to 2026 $17B = $187B EV → $105/share.
  • Historical CVS avg 10x fwd EPS → aligns.

Valuation Range: $95–$125/share (25%+ upside from $72). Strong buy below $80; hold above $110.

Investment Recommendation

Accumulate CVS aggressively below $80. FCF safety net funds 3.7% yield + buybacks; catalysts like Aetna margins and clinics outweigh MA risks. Not a trap—chatter ignores integration synergies and scale moat. Monitor Q1 earnings for execution.[29]